To find out if giving blinatumomab as injections under the skin and olverembatinib can help to control the disease in patients with Ph-positive ALL.
Performance status ≤2 (ECOG Scale).
Total serum bilirubin <2 x upper limit of normal (ULN), unless due to Gilbert's syndrome
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <3 x ULN.
Adequate pancreatic function as defined by serum lipase and amylase <1.5 x ULN.
Active serious infection not controlled by oral or IV antibiotics.
Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or squamous cell carcinoma) that in the investigator's opinion will shorten survival to less than 1 year.
Participants with psychiatric illness/social situations that would limit compliance with study requirements.
Myocardial infarction, stroke, or revascularization within 3 months
Single group
Blinatumomab
DrugGiven by Iv
olverembatinib
DrugGiven by PO
safety and adverse events
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
